Steroid-resistant nephrotic syndrome (SRNS) is a disease characterized by hypoalbuminemia, proteinuria, edema and hyperlipidemia, and a cause of chronic kidney disease in the pediatric population.
Researchers from Zhuhai Grit Biotechnology Co. Ltd. recently presented preclinical characterization of a new genetically modified tumor-infiltrating lymphocyte (TIL) product, GT-216, being developed for the treatment of solid tumors.
Researchers from Biocytogen Pharmaceuticals (Beijing) Co. Ltd. presented the development of a humanized VEGFA model (B-hVEGFA mice) as a new tool for in vivo testing of VEGFA-targeting therapeutics.
Using its artificial intelligence/machine learning platform, Aurigen, Auron Therapeutics Inc. has identified histone acetyltransferase KAT2A/B as a driver of tumor cell plasticity and designed new small-molecule degraders of KAT2A/B.
Evotec SE and Variant Bio Inc. have signed a collaboration agreement to identify treatments for diseases caused by fibrosis. The partnership leverages Variant Bio’s genomic discovery capabilities and VB-Inference platform as well as Evotec’s expertise in antifibrotic drug discovery.
YS Biopharma Co. Ltd. has received clinical trial approval by the Philippine Food and Drug Administration to begin a phase I trial of its YS-HBV-002 immunotherapeutic vaccine, designed to treat chronic hepatitis B virus (HBV) infection. The trial will begin in the Philippines in June.
Dysfunction of the complement system plays an important role in the pathogenesis of renal diseases. Complement inhibitors, such as C5 inhibitors, have shown efficacy in clinical trials, but may be not sufficient to block disease progression as monotherapy.
CD276-based immunotherapy strategies have demonstrated potent antitumor activity and feasibility for clinical application in solid tumors. In urothelial bladder cancer, CD276 is also aberrantly expressed. However, the exact role of CD276 in bladder cancer tumorigenesis and its potential clinical significance remain unexplored.
The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note that we have added three critical tables, which are continuously updated:
Pfizer Inc. has described serine/threonine-protein kinase (SIK) inhibitors reported to be useful for the treatment of arthritis, cancer, osteoporosis, atherosclerosis, inflammatory bowel disease, autoimmune diseases, inflammatory disorders and pain.